Merus Labs International (NASDAQ:MSLI) Getting Somewhat Favorable Media Coverage, Analysis Finds

Media headlines about Merus Labs International (NASDAQ:MSLI) (TSE:MSL) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merus Labs International earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.6762686569863 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several research analysts have issued reports on the company. Zacks Investment Research upgraded Merus Labs International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 18th. Canaccord Genuity cut Merus Labs International to a “hold” rating and set a $1.65 target price on the stock. in a report on Thursday, May 11th. Seven research analysts have rated the stock with a hold rating, Merus Labs International presently has an average rating of “Hold” and a consensus price target of $1.35.

Shares of Merus Labs International (MSLI) remained flat at $1.30 during mid-day trading on Monday. The company’s stock had a trading volume of 9,409 shares. Merus Labs International has a 12-month low of $0.70 and a 12-month high of $1.33. The stock has a 50 day moving average of $1.20 and a 200 day moving average of $0.94.

WARNING: This piece was originally reported by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at [[permalink]].

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.